Business
Parsortix demonstrates oesophageal cancer utility
Parsortix demonstrates oesophageal cancer utility.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 2092Z\n Angle PLC\n 20 May 2021\n \n \n \n \n \n \n \n \n For immediate release\n \n \n \n \n 20 May 2021\n \n \n \n \n \n \n \n \n ANGLE plc (\"the Company\")\n \n \n \n \n \n PARSORTIX SYSTEM UTILITY DEMONSTRATED IN OESOPHAGEAL CANCER FOR THE FIRST TIME\n \n \n \n \n \n Parsortix system consistently harvests CTCs of high quality\n \n \n \n \n \n Research paves the way for downstream molecular analysis to enable targeted treatment in this hard-to-treat cancer\n \n \n \n \n \n \n ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the University Hospital Ghent, Belgium has published results of research undertaken in oesophageal cancer, using ANGLE's Parsortix® system. These are the first published results in this cancer type, with the Parsortix system now validated in 24 cancer types in 28 independent cancer research centres located across 11 countries.\n \n \n \n \n \n Researchers utilised ANGLE's marker-independent Parsortix system to isolate epithelial circulating tumour cells (CTCs) in patients and then performed cell-based image analysis to compare cell morphology and characteristics. The study validated how this workstream could be utilised for downstream molecular analysis of cancer biomarkers from single CTCs in a future study. This would enable individualised targeted therapy from a simple blood draw, with National Comprehensive Cancer Network (NCCN) guidelines recommending biomarker testing for HER2, PD-L1 and microsatellite instability to inform treatment selection. \n \n \n \n \n \n The International Agency for Research on Cancer reports that there were 600,000 cases of oesophageal cancer and 545,000 deaths in 2020. Despite an improvement in survival rates, oesophageal cancer is a deadly disease with 80% patient mortality at 5 years from diagnosis. This is in part due to late diagnosis, with 40% of patients diagnosed with metastatic disease and a further 35% diagnosed with Stage III disease. There is an urgent need for targeted treatment options to improve patient outcomes. \n \n \n \n \n \n This study analysed only one subset of CTCs: those with epithelial characteristics. The authors are planning further research, which will also investigate mesenchymal CTCs and those undergoing...